GE HealthCare Technologies Inc. Common Stock Earnings Recaps
GE HealthCare shares fell 11.2% following first quarter results, as investors reacted to a profit outlook cut driven by mounting input cost inflation—particularly in memory chips, oil, and freight. The company reduced its full-year adjusted EPS guidance despite reporting solid revenue growth, with market disappointment centered on worsening margin pressures and the reduced profit forecast for 2026.
Key takeaways
- Full-year adjusted EPS guidance was lowered by $0.15 due to an unresolved ~$250 million inflation impact, primarily from memory chips, oil, freight, and metals costs.
- Management expects to offset a portion of these costs, but more than $100 million remains as a headwind even after mitigation actions.
- First quarter top-line growth was at the high end of expectations, driven by pharmaceutical diagnostics, advanced visualization, and imaging businesses.
- A supplier recall in the pharmaceutical diagnostics segment negatively impacted profits, though management notes the issue was resolved within the quarter.
- Early innovation milestones in CT and MR platforms and continued momentum in new product launches and cloud-based acquisitions were highlighted, though key revenue contributions from major new imaging products are not expected until the first half of 2027.
GE Healthcare demonstrated solid performance in Q3 2025 with a 4% organic revenue growth driven by robust customer demand and strategic investments, despite facing tariff pressures impacting margins.
Key takeaways
- Organic revenue increased 4% year-over-year, supported by strong orders growth of 6% across all segments.
- Adjusted EPS of $1.07 reflects a 6% decrease year-over-year, impacted by tariffs, though underlying performance would be higher without this effect.
- Solid backlog of $21.2 billion underscores growth potential, aided by new multi-year enterprise deals and rising capital equipment demand.
- Strategic investment in R&D and cost mitigation initiatives are expected to enhance margins and operational efficiency going forward.
- Free cash flow reached $483 million, highlighting strong cash generation capabilities amidst ongoing investment and operational adjustments.
GE HealthCare reported solid second-quarter results, with revenue growth driven by strong orders and strategic partnerships, despite facing tariff-related pressures that impacted margins.
Key takeaways
- Revenue of $5 billion with organic growth of 2%, and a significant service revenue increase of 7% year-over-year.
- Record backlog of $21.3 billion, up $2.2 billion from the previous year, with a robust book-to-bill ratio of 1.07x.
- Adjusted EPS rose 6% year-over-year to $1.06, bolstered by improved tax rates and lower interest expenses.
- Strategic collaborations secured, including a $90 million deal with Ascension and a $250 million contract in Europe, enhancing long-term growth prospects.
- Free cash flow improved significantly, increasing by $189 million year-over-year to $7 million, attributed to better working capital management.